Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease

J Thromb Thrombolysis. 2009 Jan;27(1):82-7. doi: 10.1007/s11239-007-0172-z. Epub 2007 Nov 27.

Abstract

This study aimed to compare plasma levels of total homocysteine (tHcy) in different arterial events as well as to investigate an association between homocysteine levels and C677T polymorphism in Brazilian patients. A total of 145 subjects were enrolled in this study including 43 patients with coronary arterial disease (CAD), 21 with ischemic stroke (IS), 44 with peripheral arterial obstructive disease (PAOD) and 37 control subjects. A preliminary analysis showed significant difference for tHcy plasma levels between patients with CAD (P = 0.003) or PAOD (P = 0.03) compared to controls. However, after adjustment for sex, age, total cholesterol, LDL, diabetes, tabagism or C677T polymorphism, no significant differences were detected in tHcy levels among patients groups and controls. No significant correlation was demonstrated for C677T polymorphism and homocysteine levels. These results indicate that increased Hcy levels may not be considered an independent risk factor for atherothrombotic diseases in Brazilian patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amino Acid Substitution
  • Arterial Occlusive Diseases / epidemiology
  • Arterial Occlusive Diseases / genetics*
  • Brain Ischemia / epidemiology
  • Brain Ischemia / genetics*
  • Brazil / epidemiology
  • Comorbidity
  • Coronary Disease / epidemiology
  • Coronary Disease / genetics*
  • Female
  • Homocysteine / blood*
  • Humans
  • Hyperhomocysteinemia / epidemiology
  • Hyperhomocysteinemia / genetics*
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Mutation, Missense
  • Peripheral Vascular Diseases / epidemiology
  • Peripheral Vascular Diseases / genetics*
  • Polymorphism, Single Nucleotide*
  • Risk Factors

Substances

  • Homocysteine
  • Methylenetetrahydrofolate Reductase (NADPH2)